Urgent

CMV retinitis (AIDS)

Opportunistic infection · Ophthalmology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Reactivation CMV end-organ disease of the retina in advanced HIV (CD4 usually <50). Progressive necrotising retinitis causes irreversible vision loss; may accompany systemic CMV (colitis, oesophagitis, encephalitis). A sight-threatening, AIDS-defining emergency - the ED job is same-day ophthalmology + starting systemic therapy.

Red flags

  • Macular/central lesion or lesion adjacent to optic nerve (immediate sight threat)
  • Rapidly progressive vision loss, new floaters or field defect
  • Bilateral disease
  • Features of systemic CMV (dysphagia, colitis, encephalitis)
  • Retinal detachment

Assessment

Differential diagnosis

  • HIV retinopathy (cotton-wool spots)
  • Toxoplasma chorioretinitis
  • Ocular syphilis
  • Acute retinal necrosis (HSV/VZV)
  • Candida/fungal endophthalmitis
  • Immune recovery uveitis (IRIS)

Investigations

  • Urgent dilated fundoscopy by ophthalmology (yellow-white retinal infiltrates + haemorrhage, 'brushfire/pizza-pie')
  • CD4 count + HIV viral load
  • Assess for extraocular CMV (colitis, oesophagitis, encephalitis)
  • CMV PCR blood ± vitreous (helps resistance assessment)
  • Baseline U&E/eGFR, FBC, electrolytes before antivirals

Management

  • Urgent (same-day) ophthalmology referral + dilated exam
  • Decide if immediately sight-threatening: lesion <1500 microns from fovea or adjacent to optic nerve head
  • Sight-threatening -> intravitreal injection PLUS systemic therapy; not sight-threatening -> systemic therapy alone
  • Check renal function before foscarnet/cidofovir; check ANC/platelets before ganciclovir
  • Screen for other CMV end-organ disease
  • Start/optimise ART (usually ~2 weeks after CMV therapy; immediately if poor follow-up); monitor for immune recovery uveitis/IRIS

Drugs & doses

Oral valganciclovir 900 mg PO BID with food x14-21 days (induction), then 900 mg PO once daily (maintenance) - preferred systemic agent
IV ganciclovir 5 mg/kg/dose q12h (induction); maintenance 5 mg/kg/day - if oral not tolerated; avoid if ANC <500 or platelets <20,000
IV foscarnet 60 mg/kg/dose q8h OR 90 mg/kg/dose q12h (induction); maintenance 90-120 mg/kg/day - renal/electrolyte toxicity, needs hydration
Intravitreal ganciclovir 2.5 mg in 0.05 mL weekly x2-3, OR intravitreal foscarnet 2.4 mg/injection twice weekly (1-4 doses over 7-14 days) - for immediate sight-threatening disease, WITH systemic therapy (specialist)
Cidofovir 5 mg/kg IV weekly x2 then 5 mg/kg every other week + IV saline + oral probenecid - 3rd-line; contraindicated if Cr >1.5 mg/dL, eGFR <=55, urine protein >=100 mg/dL, or sulfa allergy
Relapse/salvage: IV ganciclovir + IV foscarnet combination (specialist)

Disposition

Urgent same-day ophthalmology; admit for IV induction or systemic CMV disease; HIV/ID for ART; close ophthalmology follow-up for monitoring and IRIS.

Complications & pitfalls

  • Blindness
  • Retinal detachment
  • Immune recovery uveitis / IRIS
  • Contralateral eye or extraocular spread
  • Drug toxicity (ganciclovir marrow suppression; foscarnet renal/electrolyte; cidofovir nephrotoxicity)
  • Endophthalmitis/vitreous haemorrhage from intravitreal injections

Exam pearls

  • CD4 almost always <50; AIDS-defining - do not delay ophthalmology
  • Continue maintenance until retinitis quiescent, treated >=3 months AND CD4 >=100 for >=3-6 months; reinitiate if CD4 drops <100
  • Ganciclovir implants are no longer manufactured
  • Valganciclovir 900 mg gives drug exposure equivalent to IV ganciclovir 5 mg/kg

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.